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ESTROGEN IN WOMEN
Dynamic changes in circulating estradiol level, in-
cluding increase at menarche and decrease at meno-
pause, occur in a woman’s lifetime. Circulating es-
tradiol levels decrease drastically during the meno-
pausal transition, though the levels differ among
races. It has been reported that estradiol levels in
both Japanese and Chinese women were lower
than those in Caucasians, Hispanic and African-
Americans (1).
Based on data obtained in a previous study (2),
we re-analyzed data for 169 healthy men and 252
healthy women aged from 40 to 85 years in the
population-based study with addition of data for
premenopausal women. Change in circulating es-
tradiol in women from the menopausal transition
to postmenopause is characterized as follows : high
estradiol level in premenopausal women is drasti-
cally decreased and estradiol level in postmeno-
pausal women is significantly lower than that in age-
matched men. Mean estradiol levels were shown to
be 20.1 pg/ml in men and 6.1 pg/ml in postmeno-
pausal women (Figure 1). This dynamic decrease in
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estradiol level induces menopausal symptoms, such
as hot flashes and night sweat, urogenital symptoms,
osteoporosis, coronary heart disease, stroke and
possibly early onset of Alzheimer’s disease in post-
menopausal women as shown in Figure 2.
However, not only estrogen but also other endo-
crinological hormones may be involved in the occur-
rence of these diseases. Little attention has been
paid to roles of endogenous androgens in women
despite the results of studies suggesting that an-
drogens may play important roles. Androgens are
known to be important for normal physiology in
women and to play key roles in the physical, sexual
and emotional well-being of women (3). Therefore,
it is necessary to take account of androgens as well
as estrogen when considering women’s health.
CHANGE IN LEVELS OF ANDROGEN IN
WOMEN
1. Changes in testosterone level in women
In women of reproductive age, daily production
of testosterone is shared equally between the ova-
ries and adrenal glands and accounts for approxi-
mately one-third of the testosterone in circulation.
Peripheral conversion of androgen precursor ster-
oids to testosterone in non-steroid producing tis-
sues accounts for the remaining two-thirds of tes-
tosterone in circulation. These ratios change after
menopause when the ovaries are in senescence. In
women, there is controversy about the direction of
circulating testosterone levels across the life span.
It has been reported that total and free testoster-
one decreased with age between 15 and 60 years
(4) and that bioavailable testosterone decreased by
approximately 28% between 25 and 85 years of age
Figure 1. Changes in serum estradiol levels in men and women.
upper panel : men, lower panel : women
Figure 2. Increased risks of diseases in postmenopausal
women.
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(5). However, it has been shown that testosterone
level did not vary during the menopausal transi-
tion from 45 to 55 years of age (6). Recent data in-
dicate that total testosterone level increased from
43 to 50 years but not thereafter (7). In a previous
study, we found that total testosterone level gradu-
ally decreased with age in women but that the
change was not significant. However, levels of free
and bioavailable testosterone showed significant de-
creases with age in women (2).
Menopausal transition is characterized by vari-
ations in cycle length and elevation in follicle-stimu-
lating hormone (FSH) level. Based on these char-
acteristics, the American Society for Reproductive
Medicine proposed the “Stages of Reproductive
Aging Workshop (STRAW) staging system” (8).
We also divided 231 healthy women into 7 stages
by regularity of menstruation and FSH level : 1)
women with regular menstruation cycle and nor-
mal FSH level (group A), 2) women with regular
menstruation cycle and elevated FSH level (10
mIU/ml) (late reproductive stage, group B), 3)
women with irregular menstruation cycle and ele-
vated FSH level (early menopausal transition, group
C), 4) women who had irregular menstruation cycle
in which the interval of amenorrhea was more than
2 months and elevated FSH level (late menopausal
transition, group D), 5) women for whom less than
1 year had passed since menopause (group E), 6)
women for whom less than 5 years had passed since
menopause (group F) and 7) women for whom
more than 5 years had passed since menopause
(group G). As can be seen in Figure 3, total testos-
terone level did not change significantly, though
there was a slight increase during the menopausal
transition. Changes in free and bioavailable testos-
terone showed patterns similar to the pattern of
changes in total testosterone. On the other hand,
estradiol level was drastically decreased but showed
a transient increase in the early menopausal tran-
sition, possibly due to an increase in FSH stimula-
tion (Figure 3). The ratio of testosterone to estradiol
(T/E), as an assessment of the balance of testoster-
one and estradiol, gradually increased during the
menopausal transition and increased significantly in
postmenopausal stages (Figure 4). A relative testos-
terone excess was found in postmenopausal women.
Torrens et al. reported that a relative androgen ex-
cess was found during the menopausal transition
and both baseline total T/E ratio and its rate of
change were associated with increased incident
metabolic syndrome independent of ethnicity (9).
Figure 3. Changes in levels of total testosterone and estradiol during the menopausal transition.
upper panel : total testosterone, lower panel : estradiol
Group A : early reproductive stage, Group B : late reproductive stage, Group C : early menopausal transition, Group D : late meno-
pausal transition, Group E : women for whom less than 1 year has passed since menopause, Group F : women for whom less than 5
years have passed since menopause, Group G : women for whom more than 5 years have passed since menopause
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2. Changes in DHEA-S level in women
Dehydroepiandrosterone (DHEA) and its sulfate
(DHEA-S) are steroid hormones mainly produced
by the adrenal zona reticularis. The daily production
rate of DHEA is 6 to 8 mg, 50% being secreted by
the zona reticularis. In women, 20% is secreted by
the ovarian theca, while the remaining amount is
derived from circulating DHEA-S catalyzed by
steroid sulfatase. Changes in DHEA-S levels with
age differ among races. Circulating DHEA-S level
showed the lowest rate of decline with advancing
age in Japanese women and the greatest decline
with advancing age in Caucasians (10). In addition,
a transient increase in DHEA-S level during late
perimenopause and early postmenopause has been
shown. As can be seen in Figure 5, we also showed
a transient increase in DHEA-S level in the meno-
pausal transition. The rise of DHEA-S during the
menopausal transition might be associated with in-
crease in luteinizing hormone. Lasley et al. reported
that a rise in DHEA-S during the menopausal tran-
sition was found in the absence of both ovaries,
suggesting that the rise in DHEA-S is most that
from the adrenal glands (11). Although its circulat-
ing level is the highest of all steroid hormones, little
is known about its physiological role. DHEA and
DHEA-S were considered to be pro-hormones ex-
erting indirect androgenic and estrogenic effects
following peripheral conversion into small amounts
Figure 5. Changes in DHEA-S levels during the menopausal transition.
Group A : early reproductive stage, Group B : late reproductive stage, Group C : early menopausal transition, Group D : late meno-
pausal transition, Group E : women for whom less than 1 year has passed since menopause, Group F : women for whom less than 5
years have passed since menopause, Group G : women for whom more than 5 years have passed since menopause
Figure 4. Changes in testosterone/estradiol ratio during the menopausal transition.
Group A : early reproductive stage, Group B : late reproductive stage, Group C : early menopausal transition, Group D : late meno-
pausal transition, Group E : women for whom less than 1 year has passed since menopause, Group F : women for whom less than 5
years have passed since menopause, Group G : women for whom more than 5 years have passed since menopause
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of testosterone and estradiol. However, this concept
may change due to the identification of a putative
specific DHEA receptor on the plasma membrane
of bovine aortic endothelial cells (12).
ACTIONS OF ENDOGENOUS ANDROGENS
1. Female androgen insufficiency
The medical field for testosterone has long ac-
cepted the importance of male sexuality, but sexual
dysfunction in women and treatment options to ad-
dress these concerns have met with great contro-
versy. Aging and menopause have been linked to
low libido, with 52.4% of naturally menopausal
women aged 40-70 years and 36.4% of surgically
menopausal women (current age 45 years) who
have undergone oophorectomy at less than 45 years
of age reporting low sexual desire (13). The decline
of androgen levels with ovarian failure and that fol-
lowing oophorectomy have sparked the hypothesis
that decreased testosterone is related to diminished
desire. In 2002, a consensus conference recom-
mended that female androgen insufficiency syn-
drome be defined by a pattern of clinical symptoms
and signs in the presence of decreased free testos-
terone and normal estrogen status. Clinical symp-
toms of the proposed deficiency state include de-
creased libido, sexual receptivity and pleasure ; a
diminished sense of well-being ; dysphoric mood
and/or blunted motivation ; and persistent unex-
plained fatigue. Clinical signs include bone loss,
decreased muscle mass and strength, adipose tissue
redistribution, decreased sexual hair and changes
in cognition or memory (14). There are many
causes of low testosterone level in women includ-
ing dysfunction of the hypothalamic pituitary axis,
surgical or medical oophorectomy, surgical or medi-
cal adrenalectomy, premature ovarian failure, Cush-
ing syndrome, radiation and /or chemotherapy and
thyroid disease. Determination of the root cause of
low androgen production in women is important
because appropriate treatment can improve the qual-
ity of life in many women.
2. Endogenous androgen and symptoms in women
1) Physical functioning
It has been reported that circulating total testos-
terone level was associated with physical function
in women aged 49-65 years (15), though a signifi-
cant association in women aged 42-52 years was
not found in another study (16). On the other hand,
DHEA-S showed a modest association with physi-
cal functioning (16) and an inverse association with
degree of physical disability in women (15). Bell et
al. reported that DHEA-S level was associated with
greater vitality in premenopausal women, while both
testosterone and DHEA-S did not make a contribu-
tion to well-being in postmenopausal women (17).
2) Depression
Associations of circulating testosterone and
DHEA-S with depressive mood are controversial.
Several studies showed no significant association
of testosterone with depressive mood (15, 18, 19),
although an inverse association of free testosterone
with depressive symptoms in elderly women has
been found (20). A recent longitudinal study has
indicated that higher testosterone levels may con-
tribute more severe depressive symptoms in women
during the menopausal transition (21). On the other
hand, lower DHEA-S level has been shown to be
associated with degree of depressive symptoms in
women aged 49-65 years (15). Several studies have
shown a significant association of low DHEA-S level
with the presence of depressive symptoms in older
women (20, 22, 23), while discordant results were
obtained in other studies (24, 25).
3) Cognitive function
Testosterone may protect the brain from Al-
zheimer’s disease by regulating accumulation of β -
amyloid protein as well as neuroprotective action
(26). However, the association of endogenous tes-
tosterone level with cognitive function is still con-
troversial, and sex-differential association of testos-
terone level with cognitive performance has been
found (27, 28). Ryan et al. reported that higher tes-
tosterone/estradiol predicted greater semantic mem-
ory improvement in postmenopausal women (29).
Several studies failed to find a relationship between
DHEA-S level and cognitive performance (24, 30),
though Hillen et al. reported that lower DHEA-S
level was observed in women who subsequently
developed Alzheimer’s disease (31).
4) Sexual activity
The most common clinical symptom in women
due to androgen deficiency is a pronounced reduc-
tion in libido (32). It has been reported that endo-
genous testosterone level was associated minimally
with higher sexual desire in women aged 42-52
years (16). Several studies showed a correlation be-
tween low testosterone level and decrease in libido
in premenopausal women who complained of de-
creased libido (33, 34). Alarslan et al. suggested
that low testosterone level is a predictor of sexual
T. Yasui, et al. Androgen in Postmenopausal Women16
dysfunction (35). DHEA-S level in postmenopausal
women with decreased sexual desire was also lower
than that in an age-matched control group (36). It
has been reported that levels of total testosterone,
free testosterone and DHEA-S in both pre- and post-
menopausal women with low libido were lower than
those in age-matched healthy volunteers with com-
parable BMI and menopause status (37).
3. Endogenous androgen for bone and lipid profiles
in women
1) Bone health
Androgens also play an important role in bone
physiology. Androgen receptors are found in os-
teoblasts, osteoclasts and osteocytes and they are
most abundant in the osteoblast (38). Postmeno-
pausal women with hip fracture were found to have
significantly lower free testosterone level and higher
SHBG level than those in age-matched women (39).
A cohort study showed that the relative risk of hip
fracture was increased by low free testosterone level
and high SHBG level in women aged 65 years or
older (40).
2) Lipid metabolism, cardiovascular disease and
mortality
Accumulating evidence suggests that a high level
of endogenous testosterone is associated with unfa-
vorable lipid profiles, events of cardiovascular dis-
ease and insulin resistance in women. Total testos-
terone and free testosterone showed positive correla-
tions with total cholesterol, low-density lipoprotein-
cholesterol (LDL-C) and triglyceride (TG) and
negative correlations with high-density lipoprotein
(HDL)-C (41, 42). A high level of free testosterone
is associated with increases in events of cardiovas-
cular disease (43, 44) and insulin resistance (45,
46). Recently, a high testosterone level has been
shown to be associated with subclinical atherosclero-
sis in healthy menopausal women (47). In our popu-
lation-based study, free testosterone level was posi-
tively associated with BMI in women but not in men
(Figure 6).
On the other hand, associations of DHEA-S with
lipid metabolism, occurrence of cardiovasucular dis-
ease and mortality are controversial. Previous stud-
ies suggested that DHEA-S level did not affect the
risk of fatal cardiovascular disease (48), mortality
(49) and lipid profiles (50) in women. However,
Trivedi et al. reported that the highest mortality rate
was observed in the highest DHEA-S quartile in eld-
erly women aged 65-76 years, while the highest
mortality rate was found in the lowest DHEA-S
quartile in elderly men (51). We showed that DHEA-
S level was positively correlated with LDL-C in
Japanese women (52). Recent accumulating evi-
dence suggests that DHEA-S has a vasculoprotec-
tive role. Yoshida et al. reported that DHEA-S was
associated with increased carotid blood flow in eld-
erly women (53). Lower DHEA-S levels may be re-
lated to higher cardiovascular mortality in postmeno-
pausal women with CVD risk factors (54). Lower
DHEA-S level has been shown to be associated
with increased arterial stiffness in menopausal
women (47). Casson et al. reported that higher
Figure 6. Associations of free testosterone with BMI in men and women.
left panel : men, right panel : women
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testosterone level was related to greater maximal
aerobic capacity and reduced adiposity and that
higher DHEA-S level was correlated with greater in-
sulin sensitivity, suggesting that endogenous andro-
gens may play a role in the maintenance of benefi-
cial patterns of metabolic, morphometric and func-
tional parameters in postmenopausal women (55).
4. Endogenous androgen and breast cancer in
women
The mechanism by which estrogens can promote
the growth of breast cancer has been clearly shown.
However, the role of androgens is less clear, al-
though it has been shown that androgens can di-
rectly stimulate the growth of human breast cancer
cell lines (56). It has been reported that high levels
of both testosterone and estradiol in serum precede
breast cancer in postmenopausal women (57). An
analysis of worldwide prospective studies showed
strong associations of testosterone and DHEAS with
breast cancer risk in postmenopausal women (58).
Similar conclusions were obtained from a case-
control study (59) and a large multicentric cohort
study (60). A recent study has shown that high cir-
culating levels of total and free testosterone are as-
sociated with the risk of developing breast cancer
in postmenopausal women, while circulating estra-
diol level is not associated with the risk of breast
cancer (61). High total testosterone was also sig-
nificantly associated with increased risk of estrogen
receptor-positive cancers. However, Danforth et al.
reported that there were no significant associations
between the score of breast cancer risk and levels
of androgens such as testosterone, free testosterone
and DHEA-S (62).
SUPPLEMENTATION OF TESTOSTERONE
AND DHEA-S IN WOMEN
For women suffering from androgen deficiency,
the option of exogenous testosterone therapy is
available. Considerable progress has been made in
recent years in the development of different modali-
ties of testosterone therapy available to women.
Transdermal testosterone patches as well as creams
and gels are easily applied to the skin. Goldstat et
al. reported that application of testosterone cream
for 12 weeks improved well-being, mood, and sex-
ual function without any adverse effects in premeno-
pausal women with low libido and low testosterone
level (63). It has been reported that transdermal
testosterone at a dose of 300 μg/day was effective
for sexual desire in surgically and naturally meno-
pausal women (64) and in women with hypoactive
sexual desire disorder after surgically induced
menopause (65, 66) without any relevant side ef-
fects. Davis et al. also reported that transdermal
testosterone treatment resulted in a modest im-
provement in sexual function in postmenopausal
women (67). Burger et al. reported that implants
of estradiol and testosterone in postmenopausal
women improved loss of libido, tiredness and lack
of concentration (68). The results of Cochrane Re-
view meta-analysis showed that hormone therapy
(HT) plus testosterone improved libido, sexual func-
tion and sexual activity compared to the effects of
HT alone (69). Barrett-Connor et al. reported that
both estrogen alone and estrogen plus testosterone
increased BMD at the hip and spine but that high-
dose combination of estrogen and testosterone had
the greatest effect in surgically menopausal women
(70). Therefore, testosterone has a favorable effect
on sense of well-being, increases BMD and im-
proves general fatigue, sexual function and sexual
activity. On the other hand, it has been reported
that short-term testosterone treatment had no effect
on verbal fluency and verbal memory in healthy
postmenopausal women (71).
There is still considerable controversy regarding
the use of testosterone therapy in women. Reported
risks and side effects from testosterone therapy in-
clude the development of hirsutism, acne, alopecia,
liver dysfunction, deepening of the voice, abnor-
mal lipid changes, and virilization of a female fetus
if pregnant. Another major concern of testosterone
therapy is whether there is a stimulatory effect on
the breast or endometrium. Proposed mechanisms
include conversion to estrogen by the aromatase
enzyme in breast tissue or direct stimulation of the
androgen receptor. A prospective cohort study in
the Nurses’ Health Study showed that there was an
increased relative risk for breast cancer in women
using estrogen plus testosterone in comparison with
that in women who had never used estrogen plus
testosterone and that the risk was significantly
greater than the risk of estrogen alone therapy (72).
However, most of the available data do not support
the concept of increase in the risk of breast cancer
by testosterone but rather suggest that there is no
effect or that testosterone reduces the risk of breast
cancer by antagonizing the effects of estrogen on
mammary tissue (73). On the other hand, there is
a lack of data on endometrial safety. Panzer et al.
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reported that testosterone replacement therapy for
surgically and naturally menopausal women with low
sexual desire can be used safely without increased
risk of breast or endometrial cancer (74).
There does not appear to be an increase in car-
diovascular risk through alterations in blood pres-
sure, vascular reactivity, blood viscosity, hemoglo-
bin concentrations, coagulation factors, or insulin
sensitivity, with the exception of a lowering of HDL
with oral testosterone (73). In addition, there does
not appear to be an increased risk of hepatotoxicity.
In particular, a transdermal patch or gel that avoids
first pass has no related hepatic toxicity (75). The
current recommendation for testosterone treatment
is that therapy should be restricted to short-term
therapy until long-term safety issues have been re-
solved. The number of adverse events associated
with testosterone replacement treatment in women
has been limited when protocols of treatment are
optimized to achieve physiologic levels of circulat-
ing testosterone (67).
The physiological role of DHEA is poorly under-
stood. Despite the wide use of DHEA as a dietary
supplement, no well-designed study has established
the efficacy and safety of DHEA therapy. None of
the double-blind placebo-controlled studies have
shown beneficial effects of DHEA administration on
cognition, attention or memory (76). Wolkowitz et
al. only reported that DHEA treatment had signifi-
cant beneficial effects on depressive symptoms in
patients with major depression (77). Cameron et al.
suggested that doses of 30 to 50 mg of oral DHEA
produce physiological androgen levels and that 50
mg of DHEA increases serum androgen levels
within the physiological range as well as possible
improvements of sexual function and mood and
decrease in fatigue/exhaustion in women (78). A
recent study has revealed that intravaginal admini-
stration of DHEA can be used to treat vaginal atro-
phy (79). However, since DHEA is converted not
only into testosterone but also into small amounts
of estradiol, DHEA treatment may have a risk for
breast cancer in postmenopausal women. Thus,
DHEA therapy should share the contraindications
for use of estrogen replacement therapy in women.
EFFECTS OF TESTOSTERONE-DERIVED
PROGESTOGENS IN WOMEN
Hormone replacement therapy (HRT) is available
for women with menopausal symptoms. Addition
of progestogen is needed with estrogen for HRT in
women with an intact uterus even if the dose of
estrogen is low since it has been reported that en-
dometrial hyperplasia and endometrial cancer oc-
curred in women with an intact uterus when ultra-
low dose estrogen alone was used (80). Progesto-
gens, such as medroxyprogesterone, levonorgestrel
and norethisterone acetate, which are older pro-
gestogens, have androgenic activities (81). Estrogen
has favorable effects on insulin sensitivity, blood
pressure and lipid metabolism, but androgenic ac-
tivities of progestogens have unfavorable effects on
these favorable effects of estrogen. In particular,
testosterone-derived progestogens, such as lev-
onorgestrel and norethisterone, have been reported
to be associated with increase in the risk of breast
cancer (82). Therefore, it is necessary to pay atten-
tion to lipid metabolism, insulin sensitivity and risk
of breast cancer when using a testosterone-derived
progestogen.
EFFECTS OF SHBG ON ANDROGEN
Consideration of only the total testosterone level
is inadequate for assessing the androgen environ-
ment. Less than 2% of testosterone circulates in an
absolute free state in the blood at any one time.
Approximately 60-65% of testosterone is carried in
peripheral blood bound to SHBG, and testosterone
circulates in appreciable amounts bound to albumin
(35-40%) and in small amounts bound to corticoster-
oid-binding globulin (CBG) (5%). Since the bind-
ing to albumin and CBG is relatively weak, testos-
terone can easily disassociate from these proteins
to interact with the testosterone receptor. Essen-
tially, SHBG has a function as a circulating reser-
voir of this potent androgen.
1. Change in SHBG
In women, the change in circulating SHBG with
age is still controversial. SHBG has been demon-
strated to decline steadily with age (7). However,
it has been reported that SHBG was virtually un-
changed in women, while SHBG in men increased
more than 2 fold over the life span (5). Our popula-
tion-based study showed that SHBG level in women
gradually decreased around menopause and in-
creased with age after menopause, while SHBG
level was positively correlated with age in men
(Figure 7). In addition, SHBG levels show a U-
shape pattern in the 7 stages during menopausal
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transition as can be seen in Figure 8.
2. Action of SHBG
Many studies have shown associations of SHBG
with favorable effects on lipid profiles and insulin
sensitivity in men (83, 84). In women, a high SHBG
level was also associated with favorable lipid pro-
files decrease in the occurrence of cardiovascular
disease and metabolic syndrome. SHBG was shown
to be negatively correlated with total cholesterol,
LDL-C and TG and to be positively correlated with
HDL-C (42, 85). Low SHBG level was associated
with the occurrence of cardiovascular disease (43,
44). SHBG level was negatively associated with
hyperinsulinemia (86) and risk of metabolic syn-
drome (16, 87). We also showed that SHBG level
Figure 7. Changes in SHBG levels in men and women.
upper panel : men, lower panel : women
Figure 8. Changes in SHBG levels during the menopausal transition.
Group A : early reproductive stage, Group B : late reproductive stage, Group C : early menopausal transition, Group D : late meno-
pausal transition, Group E : women for whom less than 1 year has passed since menopause, Group F : women for whom less than 5
years have passed since menopause, Group G : women for whom more than 5 years have passed since menopause
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was negatively correlated with Homeostasis Model
Assessment (HOMA) index in both men and women
(88). In addition, SHBG level was negatively corre-
lated with TG level in women but not in men. There-
fore, SHBG may have biological functions beyond
simply regulation of the level of free sex steroid
hormones and may play important roles in lipid
metabolism and insulin sensitivity.
SITE OF ANDROGEN PRODUCTION IN
POSTMENOPAUSAL WOMEN
Whether ovaries produce androgens in postmeno-
pausal women is a matter of debate. It has been re-
ported that circulating androgens in postmenopausal
women do not originate from the ovaries but from
the adrenal gland since levels of androgens in post-
menopausal women with natural menopause and
those with surgical menopause were not different
(89). It was later shown in a cross-sectional study
that total and free testosterone levels in women
aged 55 years or older with bilateral oophorectomy
were significantly lower than those in age-matched
women (90). A longitudinal study also showed a
42% decline in testosterone level in postmenopausal
women who underwent oophorectomy, suggesting
that the postmenopausal ovary is hormonally active
and contributes significantly to the circulating pool
of testosterone (91). Several studies also showed
that women with bilateral oophorectomy had lower
testosterone levels than those in natural postmeno-
pausal women (92-94). Bui et al. reported that a
significant decrease was found in testosterone lev-
els after bilateral oophorectomy, whereas no signifi-
cant difference was found after natural menopause
by using the developed isotope dilution-liquid chro-
matography-tandem mass spectrometry (95). How-
ever, more recently, it has been shown that levels
of testosterone and DHEA-S did not differ signifi-
cantly between surgically and naturally menopausal
women with a mean age of 52.4 years (96).
MEASUREMENT OF TESTOSTERONE
Ability to measure either total or free testoster-
one level accurately is essential for establishing
the diagnosis of true androgen deficiency. The nor-
mal circulating level of testosterone in both repro-
ductive-aged women and postmenopausal women
still needs proper validation since methods for
measurement of testosterone have been inadequate
in women until now (97). Recent advances with the
use of ultrasensitive methods such as mass spec-
trometry coupled to either gas or liquid chromatog-
raphy have improved the technology for measure-
ment of testosterone. Advances in technology may
allow clinicians to better define female androgen
deficiency and may provide easier treatment options
for testosterone replacement therapy.
CONCLUSION
Extreme levels of circulating androgens, whether
high or low, may have negative effects on women’s
health. An excess endogenous testosterone level
may be associated with unfavorable lipid profiles, in-
sulin resistance and development of breast cancer
in postmenopausal women. On the other hand, in-
sufficiency of testosterone leads to an impairment in
sexual drive, reduced libido, and depressed mood.
For optimal physiological and psychological health
in women, circulating testosterone levels should be
within normal ranges (Figure 9). An appropriate
level of androgen may play important roles in meta-
bolic, psychological and sexual functions in women.
Although testosterone level was not significantly low
in postmenopausal women as shown in Figure 3,
various symptoms and diseases due to insufficiency
of testosterone in postmenopausal women might
be caused by individual difference or SHBG level.
In addition, very small changes in testosterone in
postmenopausal women may influence on the symp-
toms and diseases. According to the estrogen thresh-
old hypothesis proposed by Barbieri, tissues vary in
their sensitivity to estradiol (98). As well as estro-
gen, sensitivity to androgen may be different in vari-
ous tissues even if the range is narrow. In addition,
the roles of testosterone and DHEA-S in women’s
health may be different. Further studies on testos-
terone, DHEA-S and SHBG in women are needed.
Figure 9. Optimal testosterone level in women.
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